Last reviewed · How we verify
Estrogen and Progesterone Replacement
At a glance
| Generic name | Estrogen and Progesterone Replacement |
|---|---|
| Also known as | Estradiol (vivelle-dot), Progesterone (prometrium, progestin) |
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients
- Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters (PHASE4)
- No More Sleepless Nights in Perimenopause (PHASE4)
- Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: